Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
|
Celgene names Mark Alles to CEO position, ending internal contest |
|||||||||||||||||||
Celgene ($CELG) appointed Chief Operating Officer Mark Alles to be its next CEO, effective March 1, replacing Bob Hugin, who is heading to the executive chairman role. The announcement ended what had been an apparent horse race for the position between Alles and hematology/oncology chief Jacqualyn Fouse, who will take the COO position. Hugin, meanwhile, will be responsible for overall strategy and remain "actively involved in key business matters." The transition comes as Celgene works to break into the autoimmune diseases space and strives to hit Hugin's goal of tripling earnings by 2020. However, the company reported 2015 sales are likely to fall on the lower end of its forecast; it also fell short of analyst expectations with its 2016 forecast. Alles joins a host of new biopharma CEOs who have either already taken their positions or will shortly, including Giovanni Caforio at Bristol-Myers Squibb ($BMY), Olivier Brandicourt at Sanofi ($SNY), Kåre Schultz at Lundbeck and Stefan Oschmann at Merck KGaA. Story | Release
|
|||||||||||||||||||
